Drug Type Monoclonal antibody |
Synonyms Anti-alpha-v-beta-3 humanised monoclonal antibody, Anti-αvβ3 monoclonal antibody, Etaracizumab (USAN/INN) + [6] |
Target |
Action antagonists |
Mechanism αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09342 | Etaracizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 2 | United States | 01 Dec 2003 | |
Castration-Resistant Prostatic Cancer | Phase 2 | Belgium | 01 Dec 2003 | |
Castration-Resistant Prostatic Cancer | Phase 2 | Canada | 01 Dec 2003 | |
Castration-Resistant Prostatic Cancer | Phase 2 | Hungary | 01 Dec 2003 | |
Castration-Resistant Prostatic Cancer | Phase 2 | Israel | 01 Dec 2003 | |
Castration-Resistant Prostatic Cancer | Phase 2 | Poland | 01 Dec 2003 | |
Castration-Resistant Prostatic Cancer | Phase 2 | Russia | 01 Dec 2003 | |
Plaque psoriasis | Phase 2 | United States | 01 Dec 2003 | |
Plaque psoriasis | Phase 2 | Canada | 01 Dec 2003 | |
Rheumatoid Arthritis | Phase 2 | United States | 01 Sep 2003 |
Phase 2 | 112 | vvthpmalxa(oxpyhctamx) = tdoxkttzoa vdanrenutz (lymzidyuat ) View more | - | 01 Jun 2005 | |||
vvthpmalxa(oxpyhctamx) = fmvdnaffjt vdanrenutz (lymzidyuat ) View more |